CN113171333B - 含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法 - Google Patents
含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法 Download PDFInfo
- Publication number
- CN113171333B CN113171333B CN202110449175.0A CN202110449175A CN113171333B CN 113171333 B CN113171333 B CN 113171333B CN 202110449175 A CN202110449175 A CN 202110449175A CN 113171333 B CN113171333 B CN 113171333B
- Authority
- CN
- China
- Prior art keywords
- yolk antibody
- volume
- nano
- egg yolk
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 81
- 102000002322 Egg Proteins Human genes 0.000 title claims abstract description 38
- 108010000912 Egg Proteins Proteins 0.000 title claims abstract description 38
- 235000013345 egg yolk Nutrition 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 title claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 45
- 108091007433 antigens Proteins 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 32
- 206010000496 acne Diseases 0.000 claims abstract description 28
- 239000000427 antigen Substances 0.000 claims abstract description 28
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 27
- 230000001580 bacterial effect Effects 0.000 claims abstract description 21
- 108010010803 Gelatin Proteins 0.000 claims abstract description 20
- 239000008273 gelatin Substances 0.000 claims abstract description 20
- 229920000159 gelatin Polymers 0.000 claims abstract description 20
- 235000019322 gelatine Nutrition 0.000 claims abstract description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 20
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 19
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 18
- 239000002105 nanoparticle Substances 0.000 claims abstract description 17
- 230000003053 immunization Effects 0.000 claims abstract description 16
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 12
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 10
- 230000001815 facial effect Effects 0.000 claims abstract description 10
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 6
- 241000287828 Gallus gallus Species 0.000 claims abstract description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000011550 stock solution Substances 0.000 claims description 17
- 238000002649 immunization Methods 0.000 claims description 15
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000012154 double-distilled water Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 8
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 7
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 7
- 229960000458 allantoin Drugs 0.000 claims description 7
- 229960003237 betaine Drugs 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- 238000005538 encapsulation Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 6
- 239000000385 dialysis solution Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 239000013049 sediment Substances 0.000 claims description 5
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 229940101267 panthenol Drugs 0.000 claims description 4
- 235000020957 pantothenol Nutrition 0.000 claims description 4
- 239000011619 pantothenol Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 241000295644 Staphylococcaceae Species 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000017525 heat dissipation Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000008439 repair process Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 201000004624 Dermatitis Diseases 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 230000003780 keratinization Effects 0.000 abstract description 3
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 36
- 239000000047 product Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000003255 anti-acne Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000017448 oviposition Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000020154 Acnes Diseases 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 206010072170 Skin wound Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品技术，公开了一种含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法。本发明的目的在于提供一种安全有效，吸收效果明显，在修复滋养肌肤的同时，修护由肌肤过敏、细菌感染、皮脂腺角化异常、炎症等原因引起的痤疮的纳米修护面膜液。本发明选用明胶作为纳米粒的载体，采用溶剂挥发法制备出卵黄抗体纳米粒，由痤疮病原菌(痤疮丙酸杆菌、金黄色葡萄球菌、表皮葡萄球菌)菌体抗原和蛋白质抗原免疫鸡制备特异性鸡卵黄抗体IgY，将IgY和纳米颗粒两者复配后制成多效修护面膜液，通过抗痤疮卵黄抗体纳米制剂治疗痤疮比传统治疗方法具有更快速有效的特点，其疗效高、副作用小及防止抗菌素耐药等特点使其具有更广阔的应用前景，具有较好的社会效益和经济效益。
Description
技术领域
本发明涉及化妆品技术领域，具体是指一种含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法。
背景技术
痤疮是一种常发于青少年的慢性炎症性皮肤病，临床表现一般常见病况为粉刺、丘疹、炎症等皮损，发病病程长且不定，容易在面部遗留凹陷和增生瘢痕，因此对于青少年生活酬酢及心理影响很大。
痤疮丙酸杆菌常驻在皮肤表面，和其他皮肤常驻菌一样，正常情况下对人体没有危害，这些皮肤常驻菌一同构成了皮肤的稳态环境。治疗痤疮通常是复杂的，可能涉及使用局部抗生素，激素等。当皮肤毛孔被过剩的油脂和死皮细胞阻碍时，就会产生一种厌氧环境，痤疮丙酸杆菌(Propionibacterium acnes，Pacnes)可以加速生长。目前预防和治疗方法有限，缺乏安全可靠的疫苗诱导针对寻常痤疮的保护性免疫，市面上治疗痤疮基本是采用激素类药物，抗生素的使用破坏了正常菌群，容易引起菌群失调和耐药，对人体健康不利。
发明内容
为了克服现有技术存在的不足，本发明提供一种含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法，本发明的上述目的是通过以下技术方案实现的：
本发明的目的在于提供一种安全有效，吸收效果明显，在修复滋养肌肤的同时，修护由肌肤过敏、细菌感染、皮脂腺角化异常、炎症等原因引起的痤疮的纳米修护面膜液。由于痤疮会上调基质金属蛋白酶MMP-1的表达水平，从而降低皮肤真皮层的厚度，造成皮肤萎缩性瘢痕，即“痘坑”。而明胶的前体正是胶原蛋白，其降解后能促进皮肤伤口愈合、滋润皮肤，使皮肤得以修复。因此本发明选用明胶作为纳米粒的载体，采用溶剂挥发法制备出卵黄抗体纳米粒。
含有纳米包埋卵黄抗体的多效修护面膜液，首先进行痤疮病原菌的培养，制备细菌抗原、卵黄抗体，然后提取卵黄抗体，制备纳米明胶颗粒，采用纳米明胶颗粒包裹卵黄抗体制成纳米卵黄抗体原液，最后添加保湿剂、流动调节剂、活性成分和增湿剂，制成面膜液。
进一步的，所述的保湿剂为1，3-丁二醇、1，2-戊二醇、甘油；所述的流动调节剂为羟乙基纤维素、卡波姆、黄原胶；所述的活性成分为海藻糖、尿囊素、丝氨酸、谷氨酸；所述的增稠剂为PEG。
含有纳米包埋卵黄抗体的多效修护面膜液的制备方法，包括如下步骤：
步骤S1：痤疮病原菌的培养；
步骤S2：三种细菌的蛋白质抗原和菌体抗原制备；
步骤S3：卵黄抗体制备；
步骤S4：卵黄抗体提取；
步骤S5：纳米明胶颗粒制备；
步骤S6：纳米明胶颗粒包裹卵黄抗体；
步骤S7：制备面膜原液。
进一步的，步骤S1包括：
(1)葡萄球菌的培养
利用LB培养基培养金黄色葡萄球菌和表皮葡萄球菌，将LB培养基置于高压灭菌锅灭菌，待其冷却后在超净台中无菌接种，并放入恒温箱培养；
(2)痤疮丙酸杆菌的培养
将LB培养基调节pH6.8-7.0，随后与液体石蜡分别高温高压灭菌，待其冷却后在超净台中无菌接种痤疮丙酸杆菌，隔绝氧气迅速用橡胶塞塞紧瓶口，最后将接种后的LB培养基放在台式恒温振荡器中37℃培养。
进一步的，步骤S2包括：
利用甲醛法和煮法分别灭活这三种菌体，分别得到金黄色葡萄球菌蛋白质抗原、金黄色葡萄球菌菌体抗原、表皮葡萄球菌蛋白质抗原、表皮葡萄球菌菌体抗原、痤疮丙酸杆菌蛋白质抗原、痤疮丙酸杆菌菌体抗原。
进一步的，步骤S3包括：
从鸡场购入产蛋母鸡，不注射抗原饲养一周，确保产蛋母鸡能正常下蛋后，在鸡的颈部和翅膀皮下多点分别注射80μg步骤S2的细菌抗原，在初次免疫两周后进行第二次免疫，之后每间隔一周免疫一次，加强免疫三次。
进一步的，步骤S4包括：
采用水稀释-硫酸铵法：取免疫后的蛋黄，用超纯水稀释卵黄，卵黄和水体积比为1:8，混匀等待分层，取上清液加入等体积的饱和硫酸铵，调节pH为5.0；随后，离心后弃上清，用PBS溶解悬浮沉淀，将抗体装入透析袋中，将透析袋放入透析液里，4℃环境下持续搅拌除盐，每2h更换一次透析液，一共透析24h，制备Part D纳米卵黄抗体原液。
进一步的，步骤S5包括：
称取0.416-0.832g明胶于100mL烧杯中，加入8.3mL双蒸水，于50℃，400rpm搅拌溶解，边搅拌边加入8.3-16.6mL丙酮，室温静置20min，弃去上清液，加入10mL双蒸水，50℃，200rpm彻底溶解底部沉淀，加入1mol/L的HCl调节pH至2.5；滴加丙酮30-60mL，再加入以戊二醛和丙酮体积比为1:1000配置的溶液2-4mL，室温1000rpm持续搅拌5h，挥发丙酮及戊二醛，用双蒸水稀释10倍，使用40KD透析袋，在双蒸水中透析24h后，在-4℃静置保存。
进一步的，步骤S6包括：
调节明胶纳米颗粒溶液pH 7.0，向浓度为1mg/mL的纳米颗粒中加入终浓度为45μg/mL卵黄抗体，室温震荡2h后，进行包封率鉴定，检测释放速率。
进一步的，步骤S7包括：
(1)制备Part A：称取体积百分数为6％的1，3-丁二醇、4％的1，2-戊二醇、8％的甘油、2％的泛醇和质量百分数为0.2％的羟乙基纤维素、0.1％的卡波姆、0.2％的黄原胶、0.2％的尿囊素、1％的海藻糖、0.1％的EDTA二钠、0.5％的丝氨酸于烧杯中，混匀备用；
(2)将Part A搅拌，分散均匀至无不溶物，加热至80-85℃，转速为500rpm，保温20min，开始降温；
(3)降温至45℃，加入Part B原料：质量百分数为2％的甜菜碱和0.25％的谷氨酸，搅拌至无不溶物；
(4)加入Part C：质量百分数为0.5％的PEG，至A和B混合液中，搅拌至均匀透明，置于室温条件下，待其正常散热降温；
(5)将Part A、PartB和Part C混合，加入已制备的Part D：纳米卵黄抗体原液，搅拌均匀，三者混合液与Part D的体积比为10:1；
(6)使用300目滤布过滤出料；
(7)基础面膜稳定性测定。
本发明与现有技术相比的有益效果是：
(1)卵黄抗体易制备、成本低廉，适合量产，是良好的抗生素替代品，抗生素已对我们日常生活产生重大的危害，许多微生物都对其产生了强耐药性，若任其滥用，后果不堪设想，使用卵黄抗体可以避免使用抗生素带来的耐药危害，抗菌效果优良，在不久的未来以卵黄抗体为代表的抗生素替代品将会成为治疗疾病的主流。
(2)通过对提取出的抗体进行蛋白质纯度的检测发现水稀释-硫酸铵法提取出的IgY，条带清晰，无拖尾现象，杂蛋白少，卵黄抗体纯度高，证明水稀释-硫酸铵法优于水稀释-氯化钠法，更优于盐析法、有机溶剂沉淀法、等电点沉淀法、重金属离子沉淀法等现有技术。
(3)通过设计出抗痤疮卵黄抗体纳米制剂，卵黄抗体治疗痤疮比起传统方法有更快速的效果，其高疗效、副作用小的特点使其具有广阔的市场，具有广阔的发展前景。
(4)添加纳米颗粒，给药量少，对皮肤刺激减少，便于透皮吸收和缓释的作用。成本价格低廉，原材料易制取，适用于大量制取。
(5)将纳米卵黄制剂与面膜精华液混合，有易于其与肌肤细胞结合，有助于改善面部肌肤环境，同时也可以打开毛孔，便于药物吸收。在此同时也抑制了痤疮杆菌的生长，从根源上解决了痤疮发源，有效治疗痤疮症状。
附图说明
图1为注射菌体抗原产生特异性IgY抗体效价曲线；
图2为注射蛋白质抗原产生的特异性IgY抗体效价曲线；
图3为卵黄抗体(IgY)SDS-PAGE电泳结果图；
图4为纳米颗粒制备示意图；
图5为卵黄抗体释放百分率；
图6为面膜原液性状图片；
图7为离心实验结果性状图片；
图8为耐寒耐热测试图片；
图9为周女士使用面膜前和使用面膜后的皮肤状态；
图10为胡先生使用面膜前和使用面膜后的皮肤状态；
图11为马女士使用面膜前和使用面膜后的皮肤状态。
具体实施方式
下面通过具体实施例详述本发明，但不限制本发明的保护范围。如无特殊说明，本发明所采用的实验方法均为常规方法，所用实验器材、材料、试剂等均可从商业途径获得。
实施例1
使用特异性抗体作为抗菌药物是一种生物防治方法，这种免疫疗法可替代传统的抗生素治疗。卵黄抗体来源广泛，效果确实，安全可靠，使用方便。
现如今，面膜已成为当代年轻人青睐的日常皮肤保养用品，面膜液的成分便是对面部皮肤进行修复、疗养以及改善的关键。因此，针对痤疮，我们可以改变面膜液的常规成分，添加特异性卵黄抗体，达到皮肤清洁与修复的目的。
IgY作为替代抗生素的新型添加剂正在引起人们的关注，IgY取代抗生素，不会产生药物残留，是一种安全的绿色添加剂。
卵黄抗体作用具有特异性，例如针对痤疮丙酸杆菌的卵黄抗体纳米制剂只针对这种病原菌，不会破坏皮肤微生物稳态。另一方面由于其纳米制剂的特性，给药量少，对皮肤刺激减少。抗痤疮卵黄抗体纳米制剂，可以避免使用抗生素带来的耐药危害，其小剂量高疗效的特点还可以减少给药，减少副作用。由于纳米制剂便于透皮吸收的特点，能更加快速到达有菌的部位，发挥卵黄抗体的抗菌效果，真正起到见效快、效果好的作用，填补市场空白。卵黄抗体无残留、剂量小，符合绿色理念，更容易被青年人接受。我国畜牧业发达，蛋鸡来源丰富，制取卵黄抗体也变得方便且低成本。抗痤疮卵黄抗体纳米制剂其相比较于市面上的现有药物有着更广阔的发展空间，具有强大的市场。
本发明的目的在于提供一种安全有效，吸收效果明显，在修复滋养肌肤的同时，修护由肌肤过敏、细菌感染、皮脂腺角化异常、炎症等原因引起的痤疮的纳米修护面膜液。由于痤疮会上调基质金属蛋白酶MMP-1的表达水平，从而降低皮肤真皮层的厚度，造成皮肤萎缩性瘢痕，即“痘坑”。而明胶的前体正是胶原蛋白，其降解后能促进皮肤伤口愈合、滋润皮肤，使皮肤得以修复。因此本设计选用明胶作为纳米粒的载体，采用溶剂挥发法制备出卵黄抗体纳米粒。
步骤S1：痤疮病原菌的培养
(1)葡萄球菌的培养
利用LB培养基培养金黄色葡萄球菌和表皮葡萄球菌，将LB培养基置于高压灭菌锅灭菌，待其冷却后在超净台中无菌接种，并放入恒温箱培养；
(2)痤疮丙酸杆菌的培养
将LB培养基调节pH6.8-7.0，随后与液体石蜡分别高温高压灭菌，待其冷却后在超净台中无菌接种痤疮丙酸杆菌，隔绝氧气迅速用橡胶塞塞紧瓶口，最后将接种后的LB培养基放在台式恒温振荡器中37℃培养。
步骤S2：三种细菌的蛋白质抗原和菌体抗原制备
利用甲醛法和煮法分别灭活这三种菌体，分别得到金黄色葡萄球菌蛋白质抗原、金黄色葡萄球菌菌体抗原、表皮葡萄球菌蛋白质抗原、表皮葡萄球菌菌体抗原、痤疮丙酸杆菌蛋白质抗原、痤疮丙酸杆菌菌体抗原。
步骤S3：卵黄抗体制备
从鸡场购入产蛋母鸡，不注射抗原饲养一周，确保产蛋母鸡能正常下蛋后，在鸡的颈部和翅膀皮下多点分别注射80μg步骤S2的细菌抗原，在初次免疫两周后进行第二次免疫，之后每间隔一周免疫一次，加强免疫三次。
步骤S4：卵黄抗体提取
采用水稀释-硫酸铵法：取免疫后的蛋黄，用超纯水稀释卵黄，卵黄和水体积比为1:8，混匀等待分层，取上清液加入等体积的饱和硫酸铵，调节pH为5.0；随后，离心后弃上清，用PBS溶解悬浮沉淀，将抗体装入透析袋中，将透析袋放入透析液里，4℃环境下持续搅拌除盐，每2h更换一次透析液，一共透析24h，制备Part D纳米卵黄抗体原液。
步骤S5：纳米明胶颗粒制备
称取0.416-0.832g明胶于100mL烧杯中，加入8.3mL双蒸水，于50℃，400rpm搅拌溶解，边搅拌边加入8.3-16.6mL丙酮，室温静置20min，弃去上清液，加入10mL双蒸水，50℃，200rpm彻底溶解底部沉淀，加入1mol/L的HCl调节pH至2.5；滴加丙酮30-60mL，再加入以戊二醛和丙酮体积比为1:1000配置的溶液2-4mL，室温1000rpm持续搅拌5h，挥发丙酮及戊二醛，用双蒸水稀释10倍，使用40KD透析袋，在双蒸水中透析24h后，在-4℃静置保存。
步骤S6：纳米明胶颗粒包裹卵黄抗体
调节明胶纳米颗粒溶液pH 7.0，向浓度为1mg/mL的纳米颗粒中加入终浓度为45μg/mL卵黄抗体，室温震荡2h后，进行包封率鉴定，检测释放速率。
步骤S7：制备面膜原液
(1)制备Part A：称取体积百分数为6％的1,3-丁二醇、4％的1,2-戊二醇、8％的甘油、2％的泛醇和质量百分数为0.2％的羟乙基纤维素、0.1％的卡波姆、0.2％的黄原胶、0.2％的尿囊素、1％的海藻糖、0.1％的EDTA二钠、0.5％的丝氨酸于烧杯中，混匀备用；
(2)将Part A搅拌，分散均匀至无不溶物，加热至80-85℃，转速为500rpm，保温20min，开始降温；
(3)降温至45℃，加入Part B原料：质量百分数为2％的甜菜碱和0.25％的谷氨酸，搅拌至无不溶物；
(4)加入Part C：质量百分数为0.5％的PEG，至A和B混合液中，搅拌至均匀透明，置于室温条件下，待其正常散热降温；
(5)将Part A、PartB和Part C混合，加入已制备的Part D：纳米卵黄抗体原液，搅拌均匀，三者混合液与Part D的体积比为10:1；
(6)使用300目滤布过滤出料；
(7)基础面膜稳定性测定。
实施例2抗体浓度检测
用BCA法测定一免后10天和35天的IgY浓度。一免后10天的蛋白浓度为4.465μg/mL，一免后35天的蛋白浓度为22.03μg/mL。
实施例3卵黄抗体效价检测
(1)针对菌体抗原的卵黄抗体效价检测
根据图1可知病原菌菌体抗原的特异性IgY的效价于第一次免疫后第6周或第7周达到高峰，其中抗金黄色葡萄球菌特异性卵黄抗体最高效价达到1:4096，且持续维持2周；抗表皮葡萄球菌特异性IgY效价于一免后第7周达到高峰为1:2048；抗痤疮丙酸杆菌特异性IgY效价于一免后第6周达到高峰效价为1:512。
(2)针对蛋白质抗原的卵黄抗体效价检测
根据图2可知病原菌蛋白质抗原的特异性IgY的效价于第一次免疫后第7周或第8周达到高峰，其中抗金黄色葡萄球菌特异性卵黄抗体最高效价达到1:2048；抗表皮葡萄球菌特异性IgY效价于一免后第7周达到高峰为1:1024；抗痤疮丙酸杆菌特异性IgY效价于一免后第7周达到高峰，效价为1:800。
实施例4运用聚丙烯酰胺凝胶电泳(SDS-PAGE)检测蛋白纯度
图3中1号条带和3号条带是水稀释-氯化钠法提取的IgY，通过与market条带比对，虽然存在卵黄抗体但纯度不高，含有大量杂蛋白；4号条带和5号条带是通过水稀释-硫酸铵法提取出的IgY，条带清晰，无拖尾现象，杂蛋白少，卵黄抗体纯度高。水稀释-硫酸铵法优于水稀释-氯化钠法。因此，本发明采用水稀释-硫酸铵法进行卵黄抗体检测。
实施例5体外抑菌实验
最小抑菌浓度(MIC)是微生物对药物敏感性的指标。
表1特异性IgY的MIC值测定结果
实施例6检测纳米明胶颗粒包裹卵黄抗体包封率及释放速度
(1)包封率
计算纳米颗粒包封率为Mn-GNP80.18±1.42％，其中包封率＝沉淀中GFP/加入GFP总量×100％。
(2)释放速率
将包裹了卵黄抗体的纳米颗粒，10000rpm离心10min，检测上清液蛋白含量，再取其沉淀用含0.025％胰酶的PBS重悬，在37℃震荡，继续离心后检测不同时间段的上清液的蛋白含量，计算不同时间卵黄抗体的释放率，其中释放率＝上清中蛋白含量/总的蛋白含量×100％，根据图5可知，包裹GFP的纳米颗粒，在体外模拟体内环境时，在12h内缓慢释放，在24h时基本完全释放。
实施例7主要面膜配方
(1)1,3-丁二醇
在化妆品中常做保湿剂和溶剂使用，在保湿方面，由于丁二醇是小分子保湿成份，所以抓水比例很小，同时也有一定的抑菌作用。
(2)卡波姆、聚丙烯酸、羧基乙烯共聚物
属于亲水性稠化剂、稳定乳化剂、悬浮剂、凝胶剂，具有良好的透明度。
(3)1,2-戊二醇
1,2-戊二醇在化妆品、护肤品里主要作用是保湿剂，抗菌剂，增溶剂，风险系数为1，比较安全，可以放心使用，对于孕妇一般没有影响，1,2-戊二醇没有致痘性。1,2-戊二醇属于小分子保湿剂，是一种合成保湿剂，在化妆品和美容产品中作溶剂和防腐剂使用，有锁水和抗菌功能，且能提高防晒产品的抗水性。但该成分对眼睛有轻微的刺激，对皮肤无刺激。
(4)甘油
学名丙三醇，一种有机物，由于比较温和没有什么刺激性，它可以有保湿、滋润的作用，还可以在皮肤上形成一种保护膜。所以经常用在皮肤干燥的病人，它还可以做一些药膏或者护肤品的基质，解决皮肤干燥的一些问题。
(5)黄原胶
可作为乳化剂、稳定剂、凝胶增稠剂、浸润剂、膜成型剂等。
(6)羟乙基纤维素
HEC具有良好的增稠、悬浮、分散、乳化、粘合、成膜、保护水分和提供保护胶体等特性。
(7)甜菜碱
易溶于水，清洁污垢；中性稳定，不伤害肌肤；渗透性好；杀菌消炎，可药用。
(8)尿囊素
尿囊素具有促进细胞生长，加快伤口愈合，软化角质蛋白等生理功能，是皮肤创伤的良好愈合剂和抗溃疡药剂。可用作缓解和治疗皮肤干燥症、鳞屑性肤疾患、皮肤溃疡、消化道溃疡及炎症，对骨髓炎、糖尿病、肝硬化、痤疮均有较好疗效。
表2原料信息表
| 部分 | 原料成分 | 比例 |
| PartA(油相) | 1,3-丁二醇 | 体积百分数6％ |
| 1,2-戊二醇 | 体积百分数4％ | |
| 甘油 | 体积百分数8％ | |
| 泛醇 | 体积百分数2％ | |
| 羟乙基纤维素 | 质量百分数0.2％ | |
| 卡波姆 | 质量百分数0.1％ | |
| 黄原胶 | 质量百分数0.2％ | |
| 尿囊素 | 质量百分数0.2％ | |
| 海藻糖 | 质量百分数1％ | |
| EDTA二钠 | 质量百分数0.1％ | |
| 丝氨酸 | 质量百分数0.5％ | |
| PartB | 甜菜碱 | 质量百分数2％ |
| 谷氨酸 | 质量百分数0.25％ | |
| PartC | PEG | 质量百分数0.5％ |
| PartD | 纳米卵黄抗体原液 | 体积百分数10％ |
实施例7面膜稳定性测试
本实施例考察本发明所述多效修护面膜液的稳定性，将实施以上提供的配方，制备成效果最优的多效修护面膜液作为样品，然后将其分别置于40℃、室温25～27℃、寒冷-20℃温度环境下，观察该样品在1月，2月，3月，6月后，看样品液是否存在分层、析出，pH是否有变化，气味是否有变味，是否有颜色变化。其中，pH测试方法为，直测法。稳定性测试如表3所示。
表3稳定性测试结果
实施例8面膜原液效价检测
| 抗体名称 | 效价 |
| 抗表皮菌菌体抗原特异性IgY | 1:2048 |
| 抗表皮菌蛋白质抗原特异性IgY | 1:1024 |
| 抗金葡菌菌体抗原特异性IgY | 1:4096 |
| 抗金葡菌蛋白质抗原特异性IgY | 1:2048 |
| 抗痤疮菌菌体抗原特异性IgY | 1:512 |
| 抗痤疮菌蛋白质抗原特异性IgY | 1:800 |
实施例9多效修复面膜液样品的使用情况
本实施例提供使用本发明所述多效修复面膜液样品的使用方法，以及具体使用案例。
使用方法：清洁面部，取出配套压缩面膜，充分浸泡面膜液中10秒以上，敷于脸部20到30分钟，取下即可。
具体案例：
(1)周某某，女，20岁，皮肤初始状态：干燥，暗沉，冬季缺水皮肤脱屑，额头冒痘严重，使用本产品后状态：皮肤恢复水嫩，皮肤脱屑明显改善，额头痘痘明显消减。如图9。
(2)胡某某，男，21岁，皮肤初始状态：皮肤粗糙、泛红、油腻，面膜存在大量青春痘，使用本产品后：泛红现象明显改善，皮肤变得干爽不油腻，青春痘大量消减。如图10。
(3)马某，女，18岁，皮肤初始状态：敏感性肌肤，皮肤过敏后留下一系列皮肤问题，长痘现象明显，连续使用本产品后：皮肤恢复光泽，痘痘基本被消除干净。如图11。
以上所述实施方式仅为本发明的优选实施例，而并非本发明可行实施的全部实施例。对于本领域一般技术人员而言，在不背离本发明原理和精神的前提下对其所作出的任何显而易见的改动，都应当被认为包含在本发明的权利要求保护范围之内。
Claims (2)
1.含有纳米包埋卵黄抗体的多效修护面膜液的制备方法，其特征是，包括如下步骤：
步骤S1：痤疮病原菌的培养；
步骤S2：三种细菌的蛋白质抗原和菌体抗原制备；
步骤S3：卵黄抗体制备；
步骤S4：卵黄抗体提取；
步骤S5：纳米明胶颗粒制备；
步骤S6：纳米明胶颗粒包裹卵黄抗体；
步骤S7：制备面膜原液；
所述的步骤S1包括：
（1）葡萄球菌的培养
利用LB培养基培养金黄色葡萄球菌和表皮葡萄球菌，将LB培养基置于高压灭菌锅灭菌，待其冷却后在超净台中无菌接种，并放入恒温箱培养；
（2）痤疮丙酸杆菌的培养
将LB培养基调节pH6.8-7.0，随后与液体石蜡分别高温高压灭菌，待其冷却后在超净台中无菌接种痤疮丙酸杆菌，隔绝氧气迅速用橡胶塞塞紧瓶口，最后将接种后的LB培养基放在台式恒温振荡器中37℃培养；
所述的步骤S2包括：
利用甲醛法和煮法分别灭活这三种菌体，分别得到金黄色葡萄球菌蛋白质抗原、金黄色葡萄球菌菌体抗原、表皮葡萄球菌蛋白质抗原、表皮葡萄球菌菌体抗原、痤疮丙酸杆菌蛋白质抗原、痤疮丙酸杆菌菌体抗原；
所述的步骤S4包括：
采用水稀释-硫酸铵法：取免疫后的蛋黄，用超纯水稀释卵黄，卵黄和水体积比为1:8，混匀等待分层，取上清液加入等体积的饱和硫酸铵，调节pH为5.0；随后，离心后弃上清，用PBS溶解悬浮沉淀，将抗体装入透析袋中，将透析袋放入透析液里，4℃环境下持续搅拌除盐，每2h更换一次透析液，一共透析24h，制备Part D纳米卵黄抗体原液；
所述的步骤S5包括：
称取0.416-0.832 g明胶于100 mL烧杯中，加入8.3 mL双蒸水，于50℃，400rpm搅拌溶解，边搅拌边加入8.3-16.6 mL丙酮，室温静置20 min，弃去上清液，加入10mL双蒸水，50℃，200rpm彻底溶解底部沉淀，加入1 mol/L的HCl调节pH至2.5；滴加丙酮30-60mL，再加入以戊二醛和丙酮体积比为1:1000配置的溶液2-4mL，室温1000rpm持续搅拌5h，挥发丙酮及戊二醛，用双蒸水稀释10倍，使用40 KD透析袋，在双蒸水中透析24 h后，在-4℃静置保存；
所述的步骤S6包括：
调节明胶纳米颗粒溶液pH 7.0，向浓度为1 mg/mL的纳米颗粒中加入45μg卵黄抗体，室温震荡2h后，进行包封率鉴定，检测释放速率；
所述的步骤S7包括：
（1）制备Part A：称取体积百分数为6%的1,3-丁二醇、4%的1,2-戊二醇、8%的甘油、2%的泛醇和质量百分数为0.2%的羟乙基纤维素、0.1%的卡波姆、0.2%的黄原胶、0.2%的尿囊素、1%的海藻糖、0.1%的EDTA二钠、0.5%的丝氨酸于烧杯中，混匀备用；
（2）将Part A搅拌，分散均匀至无不溶物，加热至80-85℃，转速为500rpm，保温20min，开始降温；
（3）降温至45℃，加入Part B原料：质量百分数为2%的甜菜碱和0.25%的谷氨酸，搅拌至无不溶物；
（4）加入Part C：质量百分数为0.5%的PEG，至A和B混合液中，搅拌至均匀透明，置于室温条件下，待其正常散热降温；
（5）将Part A、Part B和Part C混合，加入已制备的Part D：纳米卵黄抗体原液，搅拌均匀，三者混合液与Part D的体积比为10:1；
（6）使用300目滤布过滤出料；
（7）基础面膜稳定性测定。
2.如权利要求1所述的含有纳米包埋卵黄抗体的多效修护面膜液制备方法，其特征是，所述的步骤S3包括：
从鸡场购入产蛋母鸡，不注射抗原饲养一周，确保产蛋母鸡能正常下蛋后，在鸡的颈部和翅膀皮下多点分别注射80μg步骤S2的各种细菌抗原，在初次免疫两周后进行第二次免疫，之后每间隔一周免疫一次，加强免疫三次。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110449175.0A CN113171333B (zh) | 2021-04-25 | 2021-04-25 | 含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110449175.0A CN113171333B (zh) | 2021-04-25 | 2021-04-25 | 含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113171333A CN113171333A (zh) | 2021-07-27 |
| CN113171333B true CN113171333B (zh) | 2024-02-13 |
Family
ID=76925956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110449175.0A Active CN113171333B (zh) | 2021-04-25 | 2021-04-25 | 含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113171333B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114558130B (zh) * | 2022-03-19 | 2023-11-14 | 广西博生生物科技有限公司 | 一种胶原蛋白与抗痤疮丙酸杆菌γ蛋白组合制剂的制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02121910A (ja) * | 1988-10-28 | 1990-05-09 | Kanebo Ltd | にきび用化粧料 |
| KR20020057785A (ko) * | 2001-11-13 | 2002-07-12 | 이남형 | 프로피오니박테리움 아크네스, 스타필로코커스에피더미디스, 대장균에 대한 특수면역단백질의 생산방법및 상기 방법으로 생산된 복합특수면역단백질을 함유한여드름질환예방 피부용 화장품 |
| JP2002316943A (ja) * | 2001-04-17 | 2002-10-31 | Pharmafoods Kenkyusho:Kk | 抗ニキビ組成物及びそれを含有するニキビ用化粧料 |
| CN1544471A (zh) * | 2003-11-17 | 2004-11-10 | 珠海百奥生物技术有限公司 | 抗牛乳腺炎的卵黄抗体及其制备方法和制剂 |
| CN102205122A (zh) * | 2011-05-05 | 2011-10-05 | 广西壮族自治区兽医研究所 | 一种利用喷雾干燥法制备抗仔猪腹泻卵黄抗体微胶囊的方法 |
| CN110801406A (zh) * | 2019-11-27 | 2020-02-18 | 成都格瑞珂诗生物科技有限公司 | 一种多效修护面膜液及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060198849A1 (en) * | 2003-02-25 | 2006-09-07 | Shing Paau | Preparation method of igy for preventing and cure mouth disease and the toothpaste base on the igy |
-
2021
- 2021-04-25 CN CN202110449175.0A patent/CN113171333B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02121910A (ja) * | 1988-10-28 | 1990-05-09 | Kanebo Ltd | にきび用化粧料 |
| JP2002316943A (ja) * | 2001-04-17 | 2002-10-31 | Pharmafoods Kenkyusho:Kk | 抗ニキビ組成物及びそれを含有するニキビ用化粧料 |
| KR20020057785A (ko) * | 2001-11-13 | 2002-07-12 | 이남형 | 프로피오니박테리움 아크네스, 스타필로코커스에피더미디스, 대장균에 대한 특수면역단백질의 생산방법및 상기 방법으로 생산된 복합특수면역단백질을 함유한여드름질환예방 피부용 화장품 |
| CN1544471A (zh) * | 2003-11-17 | 2004-11-10 | 珠海百奥生物技术有限公司 | 抗牛乳腺炎的卵黄抗体及其制备方法和制剂 |
| CN102205122A (zh) * | 2011-05-05 | 2011-10-05 | 广西壮族自治区兽医研究所 | 一种利用喷雾干燥法制备抗仔猪腹泻卵黄抗体微胶囊的方法 |
| CN110801406A (zh) * | 2019-11-27 | 2020-02-18 | 成都格瑞珂诗生物科技有限公司 | 一种多效修护面膜液及其制备方法 |
Non-Patent Citations (6)
| Title |
|---|
| 《Generation and characterization of chicken egg yolk antibodies against propionibacterium acnes for the prevention of acne vulgaris"，Karthika Selvan. et al，Indian Journal of Dermatology》;Karthika Selvan等;《Indian Journal of Dermatology》;第第57卷卷(第第1期期);第15-19页 * |
| 《微囊化》;谢江;《中国优秀硕士学位论文全文数据库（电子期刊）》;第5页第2段、第6页表1-2、7页表1-3 * |
| 《明胶纳米颗粒》;杨岚等;《精细化工》;第第34卷卷(第第7期期);第775页右栏第4段 * |
| 梁明振.《实用饲料添加剂技术》.广西科学技术出版社,2008,第122-124页. * |
| 罗满林.《兽医生物制品学》.中国农业大学出版社,第119-120页. * |
| 鞠强等.《痤疮》.中国医药科技出版社,2021,第63页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113171333A (zh) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104027794B (zh) | 人脐带间充质干细胞复合细胞因子在制备修复皮肤损伤的生物制剂中的应用 | |
| DE69618018T2 (de) | Arzneimittel enthaltend botulinum toxin oder neurotoxin und herstellungsverfahren | |
| CN109498501B (zh) | 一种用于祛痘和修复皮肤的多肽组合物 | |
| Alzomor et al. | Formulation and evaluation of potash alum as deodorant lotion and after shaving astringent as cream and gel | |
| CN107184949B (zh) | 一种表皮创伤修复软膏及其制备方法 | |
| CN113171333B (zh) | 含有纳米包埋卵黄抗体的多效修护面膜液及其制备方法 | |
| CN104523473A (zh) | 一种抗痤疮微乳体系及其制备方法 | |
| US11766465B2 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
| CN108852900B (zh) | 一种含有十三肽的抗菌面膜及其制作方法 | |
| WO2019174652A2 (zh) | 一种鼠尾胶原在化妆品领域的应用 | |
| CN114225007A (zh) | 一种用于修复浅表性创面的乳清蛋白喷雾剂及制备方法 | |
| RU2636530C2 (ru) | Фармацевтическая композиция для лечения ран и ожогов | |
| CN106581741A (zh) | 一种重组人源胶原蛋白敷料及其制备方法 | |
| CN107184964A (zh) | 一种医用防护剂及其制备方法和应用 | |
| CN112135620A (zh) | 红色诺卡氏菌细胞壁骨架在治疗热损伤中的用途 | |
| CN102247374A (zh) | 四氢嘧啶及其衍生物在制备治疗皮肤创伤的药物中的应用 | |
| CN101822827A (zh) | 皮肤美容和瘢痕修复的制剂 | |
| CN112263544B (zh) | 一种盐酸利多卡因凝胶及其制备方法 | |
| CN104147044B (zh) | 一种治疗仔猪葡萄球菌性渗出性皮炎的组合物 | |
| WO2018113447A1 (zh) | 一种玉兰精华营养护肤芦荟胶 | |
| CN113274428A (zh) | 一种治疗急性瘙痒性皮肤病软膏及其制备方法 | |
| CN102552339B (zh) | 一种用于治疗腐蹄病的纳米乳药物及其制备方法 | |
| CN113230200A (zh) | 一种治疗细菌性皮肤病的软膏及其制备方法 | |
| CN114470007A (zh) | 含乳酸菌发酵产物之创伤外用组合物及其用途 | |
| CN110801406A (zh) | 一种多效修护面膜液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |